CSL: Result 2014

CSL has reported another respectable result thanks to increasing sales from its immunology powerhouse.

CSL has reported a respectable full-year result, with revenue increasing 9% in constant currency terms to US$5.5bn due to strong demand for its antibody, albumin and specialty products. Net profit increased 8% to US$1.3bn, while earnings per share rose 11% to US$2.70 thanks to CSL’s ongoing share buyback. A final unfranked dividend of $0.60 was declared (ex date 8 Sep), bringing the annual total to $1.24, for a yield of 1.8%.



{{ twilioFailed ? 'SMS Code Failed to Send…' : 'An SMS verification code has been sent ...' }}

Hi {{ user.FirstName }}

Looks like you have already taken a free trial

Please enter your payment details

We have sent you a code via SMS to {{user.DayPhone}}

please enter this code below to complete your SMS verification

We cannot send you a code via SMS to {{user.DayPhone}}

If you didn't receive SMS code please

SMS code cannot be sent due to: {{ twilioStatus }}

Please select one of the options below:

Looks you are already a member. Please enter your password to proceed

Please untick this box when using a public or shared device

Verify your mobile number to proceed...

Please check your mobile number below and press the Send Verification Code button. This will be used to complete your verification in the next step.

Please sign up for full access


Updating information

Please wait ...


{{ productPrice }} / day
( GST included )
Price $0
GST $0
Discount -{{productDiscount}}
TOTAL {{productPrice}}
  • Mastercard
  • Visa

Please click on the ACTIVATE button to finalise your membership


The email address you entered is registered with InvestSMART.

Please login or select "Don't know password"

Please untick this box when using a public or shared device

Register as a new member

(using a different email)

Related Articles